Skip to content

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

ALTA-002, a SIRPα-Directed TLR9 Agonist Antibody Conjugate, Activates Myeloid Cells and Promotes Anti-Tumor Immunity

Post navigation

Previous: Evorpacept (ALX148), a CD47 Myeloid Checkpoint Inhibitor, in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) and with Gastric/Gastroesophageal Cancer (GC); ASPEN-01

Next: A Phase 2 Study of Evorpacept (ALX148) in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); ASPEN-03

Home
Company
Science
- Evorpacept
- Publications
Pipeline
- Clinical Trials
- Expanded
  Access Policy
Careers
- Current Jobs
Investors
Contact

© ALX Oncology Inc., All rights reserved.
Privacy Policy Twitter LinkedIn